Several therapeutic regimens for COVID-19 have been studied, such as combination antiviral therapies. We aimed to compare outcome of two types of combination therapies atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r) plus hydroxychloroquine among COVID-19 patients. 108 patients with moderate and severe forms of COVID-19 were divided into two groups (each group 54 patients). One group received ATV/r plus hydroxychloroquine, and the other group received hydroxychloroquine plus LPV/r. Then, both groups were evaluated and compared for clinical symptoms, recovery rates, and complications of treatment regimens. Our findings showed a significant increase in bilirubin in ATV/r-receiving group compared to LPV/r receivers. There was also a significant increase in arrhythmias in the LPV/r group compared to the ATV/r group during treatment. Other findings including length of hospital stay, outcome, and treatment complications were not statistically significant. There is no significant difference between protease inhibitor drugs including ATV/r and LPV/r in the treatment of COVID-19 regarding clinical outcomes. However, some side effects such as hyperbilirubinemia and arrhythmia were significantly different by application of atazanavir or lopinavir.
【초록키워드】 COVID-19, Treatment, Lopinavir/ritonavir, Hydroxychloroquine, Clinical symptoms, Lopinavir, Ritonavir, combination therapy, drug, outcome, clinical outcomes, arrhythmia, Protease inhibitor, therapeutic, Complication, Other, Arrhythmias, patients, COVID-19 patients, Combination, Atazanavir, Bilirubin, Hospital stay, regimen, antiviral therapies, during treatment, Side effect, two groups, no significant difference, both groups, significant increase, treatment regimens, combination therapies, hyperbilirubinemia, significantly, evaluated, form, two group, statistically significant, both group, patients with moderate, 【제목키워드】 COVID-19,